Organon & Co | OGN - Sales Revenues

Stock Price
8.22
Daily Change
-0.07 -0.84%
Monthly
1.86%
Yearly
-44.81%
Q1 Forecast
8.28

Organon & Co reported $1.6B in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Celltrion KRW 1.03T 68.49B Sep/2025
Cspc Pharmaceutical CNY 6.62B 358.95M Sep/2025
Dianthus Therapeutics USD 396K 203K Sep/2025
Divis Laboratories Ltd INR 27.15B 3.05B Sep/2025
Gilead Sciences USD 7.8B 700M Sep/2025
Glaxosmithkline GBP 11.52B 3.54B Sep/2025
Kangmei Pharma CNY 1.37B 101.16M Sep/2025
Knight Therapeutics CAD 92.26M 3.31M Sep/2024
Laboratorios Farma EUR 448.66M 67.82M Dec/2023
Medical Developments International AUD 9.53M 1.99M Jun/2025
Merck USD 16.4B 880M Dec/2025
Neuren Pharmaceuticals AUD 14.14M 179.96M Jun/2025
Novartis USD 14.36B 478M Sep/2025
Organigram Holdings CAD 80.06M 9.27M Sep/2025
Organon & Co USD 1.6B 10M Sep/2025
Pharma Mar EUR 35.7M 20.69M Sep/2025
Qiagen NV USD 457.38M 6.06M Dec/2025
Sartorius EUR 927.6M 84.4M Dec/2025
Sino Biopharmaceutical CNY 17.57B 4.58B Jun/2025
Tilray USD 217.51M 74.75M Dec/2025